Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 4/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.33 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25600525 | 0.95 | OPRL1 (0.34) | OPRL1OPRM1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL25600327 | 0.92 | OPRL1 (0.36) | OPRL1OPRM1HRH3CHRM4CHRM1 | |
| SCHEMBL25600526 | 0.92 | OPRL1 (0.34) | OPRL1OPRM1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL25600508 | 0.88 | HRH3 (0.34) | OPRL1OPRM1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL25600504 | 0.87 | OPRL1 (0.34) | OPRL1OPRM1HRH3 | |
| SCHEMBL25600507 | 0.87 | OPRL1 (0.34) | OPRL1OPRM1HRH3 | |
| SCHEMBL25600527 | 0.84 | OPRL1 (0.38) | OPRL1OPRM1HRH3CHRM1 | |
| SCHEMBL25600528 | 0.84 | HRH3 (0.37) | OPRL1OPRM1HRH3CHRM1 | |
| SCHEMBL25605704 | 0.82 | CHRM4 (0.44) | OPRL1OPRM1HRH3CHRM4CHRM1 | |
| SCHEMBL26295556 | 0.81 | CHRNB2 (0.44) | OPRL1OPRM1CHRNB2CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | OPRL1 4834/4885OPRM1 4706/4885CHRNB2 4176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.